By UWE REINHARDT: Sally Pipes’ latest post is the most recent installment in a long-running debate over the U.S. government’s 340B drug pricing program, which requires drug manufacturers to provide drugs to certain health-care facilities at significantly reduced prices. It throws into sharp relief the truly bizarre ways by which we finance health care in this country.